Susquehanna International Group, LLP Intellia Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 417,051 shares of NTLA stock, worth $5.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

417,051

Previous 220,638 89.02%

Holding current value

$5.08 Million

Previous $4.94 Million 73.59%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $3.87 Million - $5.37 Million	196,413 Added 89.02%	417,051 $8.57 Million
Q2 2024 Aug 15, 2024	BUY	$20.02 - $27.22 $2.42 Million - $3.3 Million	121,114 Added 121.69%	220,638 $4.94 Million
Q1 2024 May 07, 2024	SELL	$23.82 - $32.8 $2.29 Million - $3.15 Million	-95,975 Reduced 49.09%	99,524 $2.74 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $2.03 Million - $2.84 Million	87,710 Added 81.37%	195,499 $5.96 Million
Q3 2023 Nov 14, 2023	SELL	$31.62 - $45.78 $2.84 Million - $4.11 Million	-89,859 Reduced 45.46%	107,789 $3.41 Million
Q2 2023 Aug 11, 2023	BUY	$34.58 - $46.03 $1.87 Million - $2.49 Million	54,046 Added 37.64%	197,648 $8.06 Million
Q1 2023 May 16, 2023	BUY	$33.3 - $44.82 $644,255 - $867,132	19,347 Added 15.57%	143,602 $5.35 Million
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $303,174 - $572,297	9,129 Added 7.93%	124,255 $4.34 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $1.94 Million - $2.58 Million	35,985 Added 45.47%	115,126 $6.44 Million
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $725,998 - $1.44 Million	18,862 Added 31.29%	79,141 $4.1 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $1.33 Million - $2.72 Million	22,854 Added 61.07%	60,279 $4.38 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $4.81 Million - $6.61 Million	-47,776 Reduced 56.07%	37,425 $4.43 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $8.74 Million - $11.7 Million	66,049 Added 344.87%	85,201 $11.4 Million
Q2 2021 Aug 11, 2021	BUY	$60.88 - $161.91 $257,339 - $684,393	4,227 Added 28.32%	19,152 $3.1 Million
Q1 2021 May 17, 2021	SELL	$46.59 - $83.68 $2.75 Million - $4.94 Million	-59,060 Reduced 79.83%	14,925 $1.2 Million
Q4 2020 Feb 16, 2021	SELL	$18.83 - $63.53 $1.34 Million - $4.53 Million	-71,253 Reduced 49.06%	73,985 $4.03 Million
Q3 2020 Nov 16, 2020	BUY	$17.47 - $24.93 $1.65 Million - $2.35 Million	94,461 Added 186.03%	145,238 $2.89 Million
Q2 2020 Aug 14, 2020	SELL	$11.14 - $22.87 $402,187 - $825,675	-36,103 Reduced 41.56%	50,777 $1.07 Million
Q1 2020 May 15, 2020	BUY	$9.44 - $15.58 $129,866 - $214,334	13,757 Added 18.81%	86,880 $1.06 Million
Q4 2019 Feb 14, 2020	SELL	$10.43 - $17.67 $26,335 - $44,616	-2,525 Reduced 3.34%	73,123 $1.07 Million
Q3 2019 Nov 14, 2019	SELL	$13.07 - $18.51 $605,951 - $858,160	-46,362 Reduced 38.0%	75,648 $1.01 Million
Q2 2019 Aug 16, 2019	BUY	$13.88 - $18.41 $226,729 - $300,727	16,335 Added 15.46%	122,010 $2 Million
Q2 2019 Aug 14, 2019	BUY	$13.88 - $18.41 $1.28 Million - $1.7 Million	92,566 Added 706.13%	105,675 $1.73 Million
Q1 2019 May 15, 2019	SELL	$12.79 - $17.62 $121,837 - $167,848	-9,526 Reduced 42.09%	13,109 $224,000
Q4 2018 Feb 14, 2019	BUY	$11.39 - $27.13 $122,920 - $292,786	10,792 Added 91.13%	22,635 $309,000
Q3 2018 Nov 14, 2018	SELL	$25.78 - $32.6 $315,805 - $399,350	-12,250 Reduced 50.84%	11,843 $339,000
Q4 2017 Feb 14, 2018	SELL	$17.39 - $31.12 $323,193 - $578,365	-18,585 Reduced 43.55%	24,093 $463,000
Q3 2017 Nov 14, 2017	BUY	$15.16 - $25.75 $646,998 - $1.1 Million	42,678	42,678 $1.06 Million

Others Institutions Holding NTLA

# of Institutions

314

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Intellia Therapeutics, Inc. Transaction History